EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Neoadjuvant Capecitabine in Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

Savanah Haidar, Alex Mlynarek, Philippe Lefrancois, Osama Roshdy, Manish Khanna, Geneviève Fortier-Riberdy, Keith Richardson, Livia Florianova, Marc Pusztaszeri, Derin Caglar, Nader Sadeghi, Michael Hier und 5 weitere

JAMA Dermatology · 2026

DOI: 10.1001/jamadermatol.2026.1331 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Dermatology, 2026. Verfasst von Savanah Haidar und 16 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Capecitabine, Skin Neoplasms, Antimetabolites, Antineoplastic, Head and Neck Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The incidence of cutaneous squamous cell carcinoma of the head and neck (cSCCHN) has increased, including among those with high-risk disease. Delays to access and initiation of care are associated with disease progression and worse outcomes. Capecitabine has previously been shown to be effective antitumor activity with low toxic effects.

Objective

To evaluate the efficacy and tolerability of neoadjuvant capecitabine (NC) in advanced cSCCHN by evaluating the clinical and pathologic stage migration. Design, Setting, and Participants This prospective case series was conducted from January 2024 to September 2025 at 2 academic centers in Montreal, Canada, and included consecutive patients with advanced cSCCHN who were awaiting surgery. The data were analyzed in November 2025.

Intervention

Two cycles of NC (1000 mg, twice daily, on days 1-14, followed by a 1-week rest period) were administered according to the Capecitabine Prior to Tumor Resection in ENT Oncology (CAPTURE) protocol, with surgical resection performed within 1 to 2 weeks after treatment completion. Main Outcomes and Measures Clinical tumor response and clinical to pathologic stage migration, defined as the comparison of initial clinical stage with the postsurgical pathologic stage.

Results

The mean (SD) age of the cohort of 15 patients was 77 (8.1) years; 6 patients (40%) were female, and 9 patients (60%) were male. Clinical tumor regression was observed in 10 of 15 patients (67%). Among those who underwent resection, 5 (42%) achieved a complete pathologic response. Two patients avoided surgery due to complete treatment response and opted to receive radiotherapy. Nonresponse occurred for 5 patients, including 1 patient who experienced progression to metastatic disease. No grade 3 or higher capecitabine-related toxic effects were reported.

Conclusions

This case series found that NC demonstrated significant tumor regression and pathologic response without severe treatment-related toxic effects. NC may be an effective treatment option for providing disease control and tumor downstaging in patients with advanced cSCCHN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CapecitabineSkin NeoplasmsAntimetabolites, AntineoplasticHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckHumansNeoadjuvant TherapyFemaleMaleProspective StudiesAgedNeoplasm StagingCutaneous Squamous Cell CarcinomaMiddle AgedTreatment OutcomeAged, 80 and over

Substanzen

CapecitabineAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
  • Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Quebec, Canada.
  • Division of Dermatology, McGill University, Montreal, Quebec, Canada.
  • Department of Pathology, McGill University, Jewish General Hospital, Montreal, Quebec, Canada.
  • Department of Pathology, McGill University Health Centre, Montreal, Quebec, Canada.
  • Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.

Zitieren

APA

Haidar, S., Mlynarek, A., Lefrancois, P., Roshdy, O., Khanna, M., Fortier-Riberdy, G., Richardson, K., Florianova, L., Pusztaszeri, M., Caglar, D., Sadeghi, N., Hier, M., Sultanem, K., Tsien, C., Bouganim, N., Esfahani, K., & Mascarella, M. A. (2026). Neoadjuvant Capecitabine in Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2026.1331

Vancouver

Haidar S, Mlynarek A, Lefrancois P, Roshdy O, Khanna M, Fortier-Riberdy G, et al. Neoadjuvant Capecitabine in Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Dermatology. 2026. doi:10.1001/jamadermatol.2026.1331

BibTeX
@article{Haidar2026,
  author = {Haidar, Savanah and Mlynarek, Alex and Lefrancois, Philippe and Roshdy, Osama and Khanna, Manish and Fortier-Riberdy, Geneviève and Richardson, Keith and Florianova, Livia and Pusztaszeri, Marc and Caglar, Derin and Sadeghi, Nader and Hier, Michael and Sultanem, Khalil and Tsien, Christina and Bouganim, Nathaniel and Esfahani, Khashayar and Mascarella, Marco A},
  title = {Neoadjuvant Capecitabine in Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck},
  journal = {JAMA Dermatology},
  year = {2026},
  doi = {10.1001/jamadermatol.2026.1331}
}
Kostenlos starten →